Short Communication

Sequence analysis of Epstein–Barr virus BALF2 gene in associated tumors and healthy individuals from southern and northern China

Department of Pathogenic Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China

Search for more papers by this author

Wen Liu

Department of Pathogenic Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China

Search for more papers by this author

Meng-he Zhao

Department of Pathogenic Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China

Search for more papers by this author

Hua Xiao

Department of Pathogenic Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China

Search for more papers by this author

Yun Wang

Department of Pathogenic Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China

Search for more papers by this author

Bing Luo

*Author for correspondence:

E-mail Address: qdluobing@163.com

https://orcid.org/0000-0002-6541-5958

Department of Pathogenic Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071, China

Search for more papers by this author

Published Online:7 Jul 2022https://doi.org/10.2217/fvl-2021-0177

View article

Abstract

Aim: The purpose of this study is to investigate the polymorphism and distribution characteristics of BALF2 gene in Epstein–Barr virus (EBV)-associated tumors (gastric cancer, nasopharyngeal carcinoma and lymphoma). Materials & methods: DNA sequences of 349 EBV-related samples were analyzed by nested PCR combined with DNA sequencing. Results: According to the phylogenetic tree, BALF2 was divided into six genotypes (BALF2-A–F). Statistically, the incidence of BALF2-E in nasopharyngeal carcinoma was higher than that in healthy people, and the incidence of BALF2-E in nasopharyngeal carcinoma in South China was higher than that in North China (p = 0.001). Conclusion:BALF2 variants in EBV-associated samples are not only tumor-specific, but also differ between northern and southern regions.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

Reference

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1(7335), 702–703 (1964).
Medline CASGoogle Scholar
2. Kimura H. EBV in T-/NK-cell tumorigenesis. Adv. Exp. Med. Biol. 1045, 459–475 (2018).
Medline CASGoogle Scholar
3. Murray PG, Young LS. An etiological role for the Epstein–Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood 134(7), 591–596 (2019).
Medline CASGoogle Scholar
4. Stanland LJ, Luftig MA. The role of EBV-induced hypermethylation in gastric cancer tumorigenesis. Viruses 12(11), 1222 (2020).
CASGoogle Scholar
5. Rowe M, Kelly GL, Bell AI, Rickinson AB. Burkitt's lymphoma: the Rosetta stone deciphering Epstein–Barr virus biology. Semin. Cancer Biol. 19(6), 377–388 (2009).
MedlineGoogle Scholar
6. Tsao SW, Tsang CM, Lo KW. Epstein–Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 372(1732), 20160270 (2017).
MedlineGoogle Scholar
7. Young LS, Rickinson AB. Epstein–Barr virus: 40 years on. Nat. Rev. Cancer 4(10), 757–768 (2004). •• An overview of the mechanism by which Epstein–Barr virus (EBV)-encoded proteins contribute to tumorigenesis.
Medline CASGoogle Scholar
8. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. Lytic cycle switches of oncogenic human gamma herpesviruses. Adv. Cancer Res. 97, 81–109 (2007). •• A discussion of unsolved mysteries about the activation of the lytic cycle.
Medline CASGoogle Scholar
9. Ragoczy T, Miller G. Role of the Epstein–Barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J. Virol. 73(12), 9858–9866 (1999).
Medline CASGoogle Scholar
10. Amon W, White RE, Farrell PJ. Epstein–Barr virus origin of lytic replication mediates association of replicating episomes with promyelocytic leukaemia protein nuclear bodies and replication compartments. J. Gen. Virol. 87(Pt 5), 1133–1137 (2006).
Medline CASGoogle Scholar
11. Zeng Y, Middeldorp J, Madjar JJ, Ooka T. A major DNA binding protein encoded by BALF2 open reading frame of Epstein–Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 239(2), 285–295 (1997).
Medline CASGoogle Scholar
12. Polack A, Delius H, Zimber U, Bornkamm GW. Two deletions in the Epstein–Barr virus genome of the Burkitt lymphoma nonproducer line Raji. Virology 133(1), 146–157 (1984).
Medline CASGoogle Scholar
13. Decaussin G, Leclerc V, Ooka T. The lytic cycle of Epstein–Barr virus in the nonproducer Raji line can be rescued by the expression of a 135-kilodalton protein encoded by the BALF2 open reading frame. J. Virol. 69(11), 7309–7314 (1995).
Medline CASGoogle Scholar
14. Dreyfus DH. Genetics and molecular biology of Epstein–Barr virus-encoded BART microRNA: a paradigm for viral modulation of host immune response genes and genome stability. J. Immunol. Res. 2017, 4758539 (2017).
MedlineGoogle Scholar
15. Mcdermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin. Otolaryngol. 26(2), 82–92 (2001). • Shows a vast selection of possible etiological factors of nasopharyngeal cancer.
Medline CASGoogle Scholar
16. Shen ZC, Luo B, Chen JN et al. High prevalence of the EBER variant EB-8m in endemic nasopharyngeal carcinomas. PLOS ONE 10(3), e0121420 (2015).
MedlineGoogle Scholar
17. Wang X, Liu X, Jia Y et al. Widespread sequence variation in the Epstein–Barr virus latent membrane protein 2A gene among northern Chinese isolates. J. Gen. Virol. 91(Pt 10), 2564–2573 (2010).
Medline CASGoogle Scholar
18. Sample J, Young L, Martin B et al. Epstein–Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B and EBNA-3C genes. J. Virol. 64(9), 4084–4092 (1990).
Medline CASGoogle Scholar
19. Cheung ST, Leung SF, Lo KW et al. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein–Barr virus from nasopharyngeal carcinoma in Hong Kong. Int. J. Cancer 76(3), 399–406 (1998).
Medline CASGoogle Scholar
20. Tsurumi T, Kobayashi A, Tamai K et al. Epstein–Barr virus single-stranded DNA-binding protein: purification, characterization, and action on DNA synthesis by the viral DNA polymerase. Virology 222(2), 352–364 (1996).
Medline CASGoogle Scholar
21. Xu M, Yao Y, Chen H et al. Genome sequencing analysis identifies Epstein–Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat. Genet. 51(7), 1131–1136 (2019). •• Two non synonymous EBV variants have been identified in BALF2 that are closely associated with nasopharyngeal cancer risk.
Medline CASGoogle Scholar
22. Weiss LM, Chen YY. EBER in situ hybridization for Epstein–Barr virus. Methods Mol. Biol. 999, 223–230 (2013).
Medline CASGoogle Scholar
23. Ikuta K, Satoh Y, Hoshikawa Y, Sairenji T. Detection of Epstein–Barr virus in salivas and throat washings in healthy adults and children. Microbes Infect. 2(2), 115–120 (2000).
Medline CASGoogle Scholar
24. Thompson JD, Gibson TJ, Higgins DG. Multiple sequence alignment using ClustalW and ClustalX. Curr. Protoc. Bioinform. Chapter 2: Unit 2.3 doi: 10.1002/0471250953.bi0203s00 (2002).
MedlineGoogle Scholar
25. Coghill AE, Pfeiffer RM, Proietti C et al. Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan. Clin. Cancer Res. 24(6), 1305–1314 (2018).
Medline CASGoogle Scholar
26. Chevallier-Greco A, Manet E, Chavrier P, Mosnier C, Daillie J, Sergeant A. Both Epstein–Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5(12), 3243–3249 (1986).
Medline CASGoogle Scholar
27. Mckenzie J, El-Guindy A. Epstein–Barr virus lytic cycle reactivation. Curr. Top Microbiol. Immunol. 391, 237–261 (2015). • Potential role of lytic infection in disease development.
Medline CASGoogle Scholar
28. El-Guindy A, Ghiassi-Nejad M, Golden S, Delecluse HJ, Miller G. Essential role of RTA in lytic DNA replication of Epstein–Barr virus. J. Virol. 87(1), 208–223 (2013).
Medline CASGoogle Scholar
29. Su MT, Wang YT, Chen YJ, Lin SF, Tsai CH, Chen MR. The SWI/SNF chromatin regulator BRG1 modulates the transcriptional regulatory activity of the Epstein–Barr virus DNA polymerase processivity factor BMRF1. J. Virology 91(9), e02114–16 (2017).
Medline CASGoogle Scholar
30. Nakayama S, Murata T, Murayama K et al. Epstein–Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein. J. Biol. Chem. 284(32), 21557–21568 (2009). •• BMRF1 enhances BALF2 promoter transcription as a coactivator of BZLF1 protein.
Medline CASGoogle Scholar
31. Coghill AE, Hildesheim A. Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. Am. J. Epidemiol. 180(7), 687–695 (2014). • Associations between antibodies against EBV proteins and the risk of EBV associated malignancies.
MedlineGoogle Scholar
32. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein–Barr virus-induced cytotoxic T-cell response. J. Exp. Med. 185(9), 1605–1617 (1997).
Medline CASGoogle Scholar
33. Da Costa VG, Marques-Silva AC, Moreli ML. The Epstein–Barr virus latent membrane protein-1 (LMP1) 30-bp deletion and XhoI-polymorphism in nasopharyngeal carcinoma: a meta-analysis of observational studies. Syst. Rev. 4, 46 (2015).
MedlineGoogle Scholar
34. Goncharova EV, Senyuta NB, Smirnova KV, Shcherbak LN, Gurtsevich VE. [Epstein–Barr virus (EBV) in Russia: infection of the population and analysis of the LMP1 gene variants in patients with EBV-associated pathologies and healthy individuals]. Vopr. Virusol. 60(2), 11–17 (2015).
Medline CASGoogle Scholar
35. Gurtsevitch VE, Iakovleva LS, Shcherbak LN et al. [The LMP1 oncogene sequence variations in patients with oral tumours associated or not associated with the Epstein–Barr]. Molekuliarnaia Biologiia 47(6), 987–995 (2013).
Medline CASGoogle Scholar
36. Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. doi:10.1158/1055-9965.Epi-20-1702 (2021) (Epub ahead of print).
Google Scholar

Vol. 17, No. 9

Supplemental Materials

Metrics

Downloaded 26 times

History

Received 16 July 2021

Accepted 22 June 2022

Published online 7 July 2022

Published in print September 2022

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fvl-2021-0177

Author contributions

B Luo and W Liu conceived the project and designed experiments. H Xiao and Y Wang mainly obtained specimens from the Affiliated Hospital of Qingdao University. C-X Yu predominantly conducted the experiments. M-H Zhao participated in performance of the experiments and the drafting of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors would like to extend our grateful thanks to all volunteers who provided us with TW samples.

Financial & competing interests disclosure

This work was supported by the Shandong Provincial Natural Science Foundation (ZR2020MH302). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

All procedures performed in this study involving human participants were in accordance with the ethical standards of the Medical Ethics Committee at the Medical College of Qingdao University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent of all subjects was obtained in writing for the collection and use of samples.

PDF download